ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 1883 • ACR Convergence 2023

    Thalamocortical Mechanisms of a Remote Mind-body Intervention for Knee Osteoarthritis Pain

    Jian Kong1, Valeria Sacca1 and Chenchen Wang2, 1Massachusetts General Hospital, Boston, MA, 2Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA

    Background/Purpose: Studies found that individuals with pain exhibit altered thalamocortical rhythm, abnormal function, and structural connectivity within the network. Effective treatment may relieve pain by…
  • Abstract Number: 2176 • ACR Convergence 2023

    Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis

    Robert J. Benschop1, Jay Tuttle1, Paul Emery2, Christoph Preuss1, Mark Daniels1, Veavi Ching-Yun Chan1, Pia Yachi1 and Ajay Nirula1, 1Eli Lilly and Company, Indianapolis, IN, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease…
  • Abstract Number: 2340 • ACR Convergence 2023

    Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis

    Omer Pamuk1, Bisma Shaikh2, Saif Khan3, Ali Abbas4, Sarah Abi Doumeth5 and sarfaraz Hasni6, 1University Hospitals Cleveland Medical Center, Cleveland, OH, 2Jinnah Sindh Medical University, Karachi, Pakistan, 3College of Medical and Dental Sciences, Birmingham, United Kingdom, 4Alabama College of Osteopathic Medicine, Dothan, AL, 5Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, 6Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: The overall management of SLE and Lupus Nephritis (LN) has significantly improved over the last four decades.Recently great therapeutic strides have been made in…
  • Abstract Number: 0354 • ACR Convergence 2023

    Open-label Phase 3 Study of Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Pharmacokinetics, Effectiveness, Safety, and Immunogenicity over 252 Weeks

    Nicolino Ruperto1, Daniel J Lovell2, Sarah Ringold3, Xie L. Xu4, Jocelyn H. Leu3, Edwin Lam3, Yuhua Wang3, Alberto Martini5 and Hermine Brunner6, 1IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, 2UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, 3Janssen Research & Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC, San Diego, CA, 5Universita degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, 6Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH

    Background/Purpose: The phase 3, Intravenous Golimumab in Pediatric Participants with Active Polyarticular-Course JIA Despite MTX (GO-VIVA) study demonstrated that golimumab (GLM) 80 mg/m2 at Week…
  • Abstract Number: 0596 • ACR Convergence 2023

    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks

    Richard Furie1, Cristina Arriens2, Kenneth Kalunian3, Marilyn Pike4, Ronald van Vollenhoven5, Coburn Hobar6, Ayanbola Elegbe6, Samantha Pomponi6, Subhashis Banerjee6, Shalabh Singhal6, Thomas Wegman7 and Eric Morand8, 1Northwell Health, Manhasset, NY, 2Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, 3University of California San Diego, La Jolla, CA, 4MedPharm consulting, Inc., Raleigh, NC, 5Amsterdam University Medical Centers, Amsterdam, Netherlands, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Beaver Falls, PA, 8Monash University, Centre for Inflammatory Diseases, Melbourne, Australia

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis. In…
  • Abstract Number: 0839 • ACR Convergence 2023

    Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study

    Peter C. Taylor1, Georg Schett2, Fowzia Ibrahim3, Bei Zhou4, Jocelyn H. Leu5, Sophia G. Liva5, Qingmin Wang5, Ricardo Rojo Cella5, Chetan S. Karyekar5 and Kaiyin Fei5, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 3Janssen Research & Development, LLC, High Wycombe, United Kingdom, 4Janssen Research & Development, LLC, Chesterbrook, PA, 5Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: RA is a chronic inflammatory disease associated with autoantibodies. Despite the use of targeted therapies, up to half of patients fail to achieve remission…
  • Abstract Number: 1339 • ACR Convergence 2023

    Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

    Ting Wang1, Natalia V. Giltiay2, Christian Lood2 and Bobby Kwanghoon Han2, 1University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Neutrophil activation and formation of neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of rheumatoid arthritis (RA). Calprotectin, a neutrophil activation marker,…
  • Abstract Number: 1498 • ACR Convergence 2023

    First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

    Giorgio Senaldi1, Aparna Mohan1, Li Zhang1, Jun Tanaka2, Grishma Pandya3, Sindee Grossman3, Sarah Urbina4, Steven Reynolds5 and Alan Hand4, 1Daiichi Sankyo, Basking Ridge, NJ, 2Daiichi Sankyo, Inc., Basking Ridge, NJ, 3Daiichi Sankyo Inc., Basking Ridge, NJ, 4Worldwide Clinical Trials, San Antonio, TX, 5Cenexel, Los Alamitos, CA

    Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor, whose ligands include nucleic acids and whose activation is part of the pathogenesis of systemic lupus…
  • Abstract Number: 1922 • ACR Convergence 2023

    Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol

    Charline Vauchy1, Maxime Desmarets1, Paul Bastard2, Anne Puel2, Pascale Richard3, Jean Laurent Casanova2, Pierre Tiberghien3, Eric Toussirot4 and Francois Aubin5, 1INSERM CIC-1431, Besançon, France, 2IHU Imagine, AP-HP Necker, Paris, France, 3Etablissement Français du Sang, St. Denis, France, 4University Hospital of Besancon, Besançon, France, 5Dermatology, University Hospital of Besancon, Besançon, France

    Background/Purpose: Hidradenitis suppurativa (HS) is a multifactorial auto-inflammatory disorder with a prevalence of 1% in North American and European populations. HS may be associated with…
  • Abstract Number: 2229 • ACR Convergence 2023

    Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies

    Laura Coates1, Iain McInnes2, Sibel Aydin3, Mitsumasa Kishimoto4, Philip J. Mease5, May Shawi6, Miriam Zimmermann7, Emmanouil Rampakakis8, Frederic Lavie9 and Dennis McGonagle10, 1University of Oxford, Oxford, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, 4Kyorin University School of Medicine, Yokohoma, Japan, 5Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 6Immunology, Janssen Research & Development, LLC, Titusville, NJ, 7Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, 8McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, 9The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, 10Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: In patients with mono/oligoarticular psoriatic arthritis (PsA), swelling or tenderness of specific joints can be associated with poorer patient-reported outcomes (PROs) and physician global…
  • Abstract Number: 2342 • ACR Convergence 2023

    Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial

    Aida Santos da Costa1, Thomas Dörner2, Andrea Grioni1, Alexandre Avrameas1, Ulrike Sommer1, Rainer Hillenbrand1, Valeria De Luca1, Enrico Ferrero1, Andre Nogueira da Costa1, Isabelle Isnardi1 and Stephen J Oliver1, 1Novartis Pharma AG, Basel, Switzerland, 2Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany

    Background/Purpose: Ianalumab (VAY736) is an afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
  • Abstract Number: 0360 • ACR Convergence 2023

    Increasing the Etanercept Dose in Juvenile Idiopathic Arthritis Patients: Does It Help Reaching the Treatment Target? A Post-hoc Analysis of the Best4Kids Randomised Clinical Trial

    Bastiaan van Dijk1, Sytske Anne Bergstra1, Merlijn van den Berg2, Dieneke Schonenberg-Meinema2, Lisette van Suijlekom-Smit2, Marion van Rossum3, Yvonne Koopman4, Rebecca Ten Cate1, CF Allaart1, Danielle Brinkman1 and Petra Hissink Muller1, 1Leiden University Medical Center, Leiden, Netherlands, 2Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam Rheumatology and Immunology Center | Reade, Amstelveen, Netherlands, 4HagaZiekenhuis Juliana Children's Hospital, The Hague, Netherlands

    Background/Purpose: The relation between etanercept dose and clinical outcomes of juvenile idiopathic arthritis (JIA) is unclear. Most studies only evaluated doses up to 0.8 mg/kg/week…
  • Abstract Number: 0598 • ACR Convergence 2023

    Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study

    Richard Furie1, Victoria Werth2, Eric Milliman3, Kyle Ferber3, Fergal Casey3, Roland Brown3, Denitza Raitcheva3, Jad Zoghbi3, Danielle Graham3, George Kong3, Youmna Lahoud3, Nathalie Franchimont4 and Catherine Barbey5, 1Northwell Health, Manhasset, NY, 2University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 3Biogen, Cambridge, MA, 4Former employee of Biogen, Cambridge, MA, 5Biogen, Baar, Switzerland

    Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…
  • Abstract Number: 0840 • ACR Convergence 2023

    Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study

    Xiaofeng Zeng1, chanyuan wu2, Jiankang Hu3, SHENGYUN LIU4, Zhenyu Jiang5, Jingyang Li6, Xiaoxia Wang7, Ju Liu8, Chaofan Yuan9, Guang Yang10 and Chris Liang10, 1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Pingxiang People’s Hospital, PingXiang, China, 4The First Affiliated Hospital Of Zhengzhou University, Zhengzhou, China, 5The First Hospital of Jilin University, Changchun, China, 6Zhuzhou Central Hospital, Zhuzhou, China, 7Second Hospital of Shanxi Medical University, Taiyuan, China, 8Jiujiang No. 1 People’s Hospital, JiuJiang, China, 9Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing, China, 10Hangzhou Highlightll Pharmaceutical Co., Ltd, HangZhou, China

    Background/Purpose: None of the currently approved treatments for rheumatoid arthritis (RA) can achieve ACR50 in >50% of the patients, and 5 – 20% of the…
  • Abstract Number: 1343 • ACR Convergence 2023

    Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years

    Xavier Mariette1, Sven Borchmann2, Sandrine Aspeslagh3, Jaime Calvo- Alén4, Richard Moriggl5, Zoltan Szekanecz6, Francesco De Leonardis7, Nadia Verbruggen8, Paul Van Hoek9, Marc Schmalzing10, Andreas Stallmach11, Christina Charles-Schoeman12, Vijay Rajendran13, Christine Rudolph9, Chris Watson14, Yoshiya Tanaka15 and Ernest Choy16, 1Université Paris-Saclay, Le Kremlin-Bicêtre, France, 2Department of Internal Medicine, University of Cologne, Cologne, Germany, 3Department of Medical Oncology, UZ Brussel, Brussels, Belgium, 4Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, 5Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria, 6Division of Rheumatology, University of Debrecen, Debrecen, Hungary, 7Medical Affairs, Galapagos GmbH, Basel, Switzerland, 8Biostatistics, Galapagos NV, Mechelen, Belgium, 9Medical Safety, Galapagos NV, Mechelen, Belgium, 10University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, 11Department of Internal Medicine, Jena University Hospital, Jena, Germany, 12UCLA Medical Center, Santa Monica, CA, 13Clinical Research, Galapagos NV, Mechelen, Belgium, 14Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, 15University of Occupational and Environmental Health, Kitakyushu, Japan, 16Section of Rheumatology, Cardiff University, Cardiff, United Kingdom

    Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor for the treatment of RA. Data from the ORAL Surveillance post-marketing study (NCT02092467) suggest…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology